{"filing":{"accession_number":"0001104659-26-109809","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"tm2625977d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926109809/tm2625977d1_8k.htm"},"events":[{"id":34465,"run_id":31711,"accession_number":"0001104659-26-109809","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Armata announced receipt of $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02, bringing cumulative DoW funding to $32.4 million. This is a material operational and strategic milestone for a late-stage biotech company advancing a clinical-stage therapeutic candidate, but does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named event types. The funding is non-dilutive and represents government support for clinical development rather than a traditional financing event.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38192,"accession_number":"0001104659-26-109809","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced receipt of $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02, bringing cumulative DoW funding to $32.4 million. This is a material operational and strategic milestone for a late-stage biotech company advancing a clinical-stage therapeutic candidate, but does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named event types. The funding is non-dilutive and represents government support for clinical development rather than a traditional financing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:11:04.396025+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38192,"accession_number":"0001104659-26-109809","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced receipt of $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02, bringing cumulative DoW funding to $32.4 million. This is a material operational and strategic milestone for a late-stage biotech company advancing a clinical-stage therapeutic candidate, but does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named event types. The funding is non-dilutive and represents government support for clinical development rather than a traditional financing event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T11:11:04.396025+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-09-23"}]}